An exploratory study to optimize the administration of COMT inhibitor on LCIG therapy

An exploratory study to optimize the administration of COMT inhibitor on LCIG therapy - Levodopa pharmacokinetics on concomitant use of LCIG therapy and COMT inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037390

Enrollment

Registered

2019-07-16

Start date

2019-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Entacapone 100mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Parkinson's disease who undergo LCIG therapy

Exclusion criteria

Exclusion criteria: Patients who have difficulty showing consent

Design outcomes

Primary

Measure	Time frame
Plasma concentration of levodopa without COMT inhibitor, with COMT inhibitor at 13 o'clock, or at 15 o'clock	—

Countries

Japan

Contacts

Public ContactYuko Hosokawa

Ehime University Hospital Department of Neurology and Clinical Pharmacology

hosokawa.yuko.ks@ehime-u.ac.jp089-960-5095

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026